FDA Approves Jakafi to treat patients with chronic type of bone marrow disease

08 Dec 2014 10:43 PM | Lori Aubrey (Administrator)

FDA Approves Jakafi to treat patients with chronic type of bone marrow disease
First FDA-approved drug for polycthemia vera On December 4, 2014, the U.S. Food and Drug Administration approved a new use for Jakafi (ruxolitinib) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Jakafi is the first drug approved by the FDA for this condition.

http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm425677.htm

Comments

Northern New England Clinical Oncology Society
P.O. Box 643
Sandown, NH 03873-0643
Telephone (603) 887-1948
info@nnecos.org

This website brought to you by:


Powered by Wild Apricot Membership Software